# Ascentage Pharma Group International American Depository Shares (AAPG) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $13.48, market value $1.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Ascentage Pharma Group International American Depository Shares reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.2×**. Each dollar of revenue is priced at 2.2×.
- **Price / book: 15.1×**. The shares trade at 15.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -95.5%** (5-yr avg -51.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 91.5%**. Ascentage Pharma Group International American Depository Shares keeps 91.5% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -208.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -216.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: -93.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -142.6%**. Return on all capital, debt included, is -142.6%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -31.4%**. Each dollar of assets produces -31.4% of profit.

## Growth
- **Revenue growth (1 yr): 327.3%**. Revenue grew 327.3% over the last year.

## Financial health
- **Debt to equity: 1.49**. Debt is 1.49 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 0.4×**. It would take 0.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: -22.2×**. Operating profit covers interest only -22.2×: fragile.
- **Current ratio: 1.79** (quick 1.77). Current assets cover the next year's liabilities 1.79 times.
- **Altman Z-score: 0.30**. A Z-score of 0.30 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Ascentage Pharma Group International American Depository Shares does not currently pay a dividend, but it returned -182.4% of its market value through buybacks over the last year.

## Price and momentum
- **Total return (1 yr): -59.4%** (YTD -48.3%, 3-mo -19.3%). The shares are down 59.4% over twelve months including dividends.
- **From 52-week high: -60.9%** (0.1% above the low). Trading 61% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 36**. An RSI of 36 is neutral.
- **Beta (1 yr): 1.32** (volatility 60%). Beta of 1.32 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AAPG · Page: https://foliofundamentals.com/stocks/aapg

Not investment advice.